Objective To compare the efficacy and safety of antithrombotic therapies between indobufen and aspirin in patients with coronary heart disease(CHD)after percutaneous coronary intervention(PCI).Methods The databases of PubMed,Cochrane Library,EMbase,CNKI and WanFang Data were retrieved with computer from database establishment time to Jan.2023.According to inclusion and exclusion criteria,all literature were screened,and data was extracted and analyzed by using RevMan 5.4 software.The subjects in included literature were divided into test group(indobufen combined with P2Y12 receptor antagonist)and control group(aspirin combined with P2Y12 receptor antagonist).The outcome indicators included the incidence of major adverse cardiovascular events(MACE),bleeding events,stroke and adverse events.Results There were totally 16 randomized controlled trials(RCT)included involved 5893 subjects,of them 2926 in test group and 2967 in control group.The Results of Meta-analysis showed that the incidence of MACE,bleeding risk and adverse events decreased after treatment with indobufen,compared with aspirin,in patients with CHD after PCI(MACE:RR=0.59,95％CI:0.43～0.80,P＜0.01;bleeding events:RR=0.55,95％CI:0.43～0.70,P＜0.01;adverse events:RR=0.31,95％CI:0.20～0.47,P＜0.01).The incidence of stroke had no statistical significance between 2 groups(RR=0.75,95％CI:0.42-1.34,P＞0.05).Conclusion The efficacy and safety of indobufen combined with P2Y12 receptor antagonist in antithrombotic treatment has a higher advantage in patients with CHD after PCI,and indobufen can be taken as an alternative drug for aspirin.
维普
万方数据